Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT02147808Phase 1Completed
Phase 1, open-label, single-arm trial of telotristat ethyl in Carcinoid Syndrome (CS), sponsored by Lexicon Pharmaceuticals, Inc. Primary endpoint: Midazolam plasma concentration in combination with steady state telotristat etiprate at Day 9. Started May 2014; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT02147808.